Rare mutations in circulating cell-free DNA may provide valuable information about disease status and treatment response for research use. The MassARRAY® System, powered by UltraSEEK™ chemistry, provides a highly sensitive and multiplexed method for detecting rare events.
With time-to-result in just a day, the MassARRAY System enables fast and cost-effective screening with a targeted set of mutations and/or orthogonal validation of next generation sequencing (NGS) and real-time PCR (RT-PCR) results, even with low frequency mutant alleles.
Detecting Low Frequency Mutations
Tumor heterogeneity presents a major obstacle to the detection of somatic mutations. With UltraSEEK chemistry by Agena Bioscience, your lab can design targeted panels to any genomic region with confidence that even low-level genetic determinants will be detected. You can perform noninvasive testing for early detection of metastasis, monitor therapeutic response, or study proliferation of a primary tumor to enable clinical research studies.
Confirming Borderline Test Results
UltraSEEK chemistry is a reliable and economical method for validating mutations of interest identified through NGS and RT-PCR to confirm or rule out borderline results. After whole-exome sequencing results are produced, targeted detection on the MassARRAY System is proven to confirm low threshold mutations with sensitivity as low as 0.1%.
How It Works
Our online Assay Design Suite software enables straightforward assay design to quickly generate panels for sequencing validation or patient-specific studies. UltraSEEK chemistry amplifies desired sequences and extends the mutant allele, which allows detection at a 0.1% level. Reporting software delivers results clearly and quickly, allowing for convenient data analysis.
Download our UltraSEEK Reagents brochure for more information.
In addition to designing your own ultrasensitive somatic mutation assays, you can purchase a predesigned panel or take advantage of our custom assay design and sample processing services.